IP Verse

Apixaban Formulations - EP3251660

The patent EP3251660 was granted to Bristol Myers Squibb Ireland on Oct 16, 2019. The application was originally filed on Feb 24, 2011 under application number EP17175788A. The patent is currently recorded with a legal status of "Revoked".

EP3251660

BRISTOL MYERS SQUIBB IRELAND
Application Number
EP17175788A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Grant Date
Oct 16, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 16, 2020TER MEER STEINMEISTER & PARTNERADMISSIBLE
STADA ARZNEIMITTELJul 16, 2020KERNEBECKADMISSIBLE
SANDOZJul 15, 2020KRAUS & LEDERER PARTGMBBADMISSIBLE
INTAS PHARMACEUTICALSJul 15, 2020ACCORD HEALTHCAREWITHDRAWN
KRKAJul 15, 2020HOEFER & PARTNER PATENTANWALTE MBBWITHDRAWN
MEDICHEMJul 14, 2020HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSJul 14, 2020D YOUNGADMISSIBLE
KUTZENBERGER WOLFF & PARTNERJul 13, 2020KUTZENBERGER WOLFF & PARTNERADMISSIBLE
ZENTIVA KSJul 10, 2020HOFFMANN EITLEADMISSIBLE
POLPHARMAJul 2, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2006069258
DESCRIPTIONUS6967208
OPPOSITIONEP2538925
OPPOSITIONEP3017811
OPPOSITIONUS2006069258
OPPOSITIONUS2006160841
OPPOSITIONUS2007259913
OPPOSITIONUS2009291913
OPPOSITIONUS6967208
OPPOSITIONUS7396932
OPPOSITIONWO2006108643
OPPOSITIONWO2007001385
OPPOSITIONWO2007022165
OPPOSITIONWO2008031782
OPPOSITIONWO2009135947
OPPOSITIONWO2010003811
OPPOSITIONWO2010147978
OPPOSITIONWO2011106478
SEARCHUS2006160841
SEARCHWO2008031782
SEARCHWO2010147978

Non-Patent Literature (NPL) Citations (110) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AMIDON, G. L. et al., Pharmaceutical Research, (19950000), vol. 12, pages 413 - 420-
OPPOSITION- "<429> LIGHT DIFFRACTION MEASUREMENT OF PARTICLE SIZE", USP. CONFERENCE ON BIOLOGICAL AND BIOTECHNOLOGICAL DRUGSUBSTANCES AND PRODUCTS, XX, XX, XX, (20150501), pages 294 - 299, XP003035295-
OPPOSITION- "<429> Light Diffraction measurement of Particle Size", US pharmacopoeia , USP, (2006), vol. 38, XP055241392-
OPPOSITION- Alan Rawle, "BASIC PRINCIPLES OF PARTICLE SIZE ANALYSIS", Malvern Technical Paper, Malvern Instruments Limited, UK, UK, (19930101), no. MRK034, pages 1 - 8, XP002772489-
OPPOSITION- AMIDON et al., "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", Pharmaceutical Research, (19950000), vol. 12, pages 413 - 420, XP055640443-
OPPOSITION- Amidon, Et Al., "A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability", Pharmaceutical Research, (19950101), vol. 12, no. 3, pages 413 - 420, XP055640443-
OPPOSITION- Amidon, Et Al, "Chapter 8", Developing solid oral dosage forms: Pharmaceutical Theory and Practice, Academic Press, (20090101), pages 163 - 167, 414-416, XP055641338-
OPPOSITION- Amidon Et Al., "Particle, Powder, and Compact Characterization", Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice 2009, (20090130), pages 163-167 ,414 - 416, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice 2009, XP055296127-
OPPOSITION- Anonymous, "<429> Light Diffraction measurement of Particle Size", US pharmacopoeia, USP 38, (20150501), pages 295 - 299, US pharmacopoeia, USP 38, (20191108), XP055640457-
OPPOSITION- Anonymous, "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation - Tabular View - ClinicalTrials.gov", ClinicalTrials.gov NCT00412984, (20130927), pages 1 - 7, ClinicalTrials.gov NCT00412984, URL: https://clinicaltrials.gov/ct2/show/record/NCT00412984?term=NCT00412984&rank= 1, (20161129), XP055323941-
OPPOSITION- Anonymous, "A randomized, double-blind palcebo-controlled study of apixaban for the prevention of thromboembolic events in patients undergoing treatment for advanced cancer: a phase 2 pilot study", ClinicalTrials.gov, NCT00320255, (20100218), pages 1 - 2, ClinicalTrials.gov, NCT00320255, (20191104), XP055638473-
OPPOSITION- Anonymous, "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", ClinicalTrials.gov, NCT00633893, (20100218), pages 1 - 4, ClinicalTrials.gov, NCT00633893, (20191104), XP055638465-
OPPOSITION- Anonymous, "A safety and efficacy trial evaluating the use of apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism", ClinicalTrials.gov, NCT00643201, (20100218), pages 1 - 4, ClinicalTrials.gov, NCT00643201, (20191104), XP055638468-
OPPOSITION- Anonymous, "Guidelines on the Investigation of Bioequivalence", EMEA Committee for Medicinal Products for Human Use., Emea European Medicines Agency, (20100120), pages 1 - 27, XP055777598-
OPPOSITION- Anonymous, "Section 2.9.31 - Particle Size Analysis by Laser Light Diffraction", European Pharmacopoeia 6.0, (20070723), pages 311 - 314, XP055638472-
OPPOSITION- Anonymous, "The Biopharmaceutics Classification System (BCS) Guidance", FDA U.S. Food & Drug, (20160101), FDA U.S. Food & Drug, URL: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm128219.htm, (20161006), XP055308403-
OPPOSITION- Anonymous, "Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", Guidance for Industry, (20000801), pages 1 - 15, Guidance for Industry, (20191108), XP055640590-
OPPOSITION- "A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) Cancer", ClinicalTrials.gov archive, View of NCT00320255, (20100218), XP055638473-
OPPOSITION- "Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation - Tabular View - ClinicalTrials.gov", NCT00412984, (20161129), URL: https://clinicaltrials. gov/ct2/show/record/NCT00412984 ?term= NCT00412984&rank= 1, XP055323941-
OPPOSITION- "APPRAISE Steering Committee and Investigators", Circulation, (20090000), vol. 119, pages 2877 - 2855-
OPPOSITION- AULTON, "Biopharmaceutics", Pharmaceutics: The Science of Dosage Form Design, (19880000), vol. 1-13, pages 135 - 173, XP055640558-
OPPOSITION- Aulton M E, "Pharmaceutics The Science of Dosage Form Design", Pharmaceutics The Science of Dosage Form Design, (20020000), pages 23 - 29, XP055308566-
OPPOSITION- C. FROST et al., "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects", J. Thromb. Haemost, (20070000), vol. 5, no. 2, XP055766184-
OPPOSITION- C. Frost, Et Al., "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects", J. Thromb. Haemost, (20070709), vol. 5, no. 2, page 1, XP055766184-
OPPOSITION- "Chapter 8", Amidon, Et Al, DEVELOPING SOLID ORAL DOSAGE FORMS: PHARMACEUTICAL THEORY AND PRACTICE, (20090000), pages 163 - 7; 414-416, XP055641338-
OPPOSITION- Clinical Trials Apixaban for the prevention of stroke NCT00412984, (20190515), XP055323941-
OPPOSITION- ClinicalTrials.gov archive, View of NCT00643201, (20100218), XP055767074-
OPPOSITION- ClinicalTrials.gov , NCT00320255, (20100218), XP055638473-
OPPOSITION- Clinical Trials.gov , NCT00643201, (20100218), XP055767074-
OPPOSITION- David Attwood, Et Al, "Dissolution of drugs", Physical Pharmacy, (20080101), page 7, XP055765090-
OPPOSITION- D. A. WADKE et al., "CHAPTER 1: Preformulation Testing", D. A. WADKE et al., PHARMACEUTICAL DOSAGE FORMS: TABLETS, (19890000), vol. 1, pages 1 - 9, XP009184711-
OPPOSITION- Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, "CHAPTER 1: Preformulation Testing", Deodatt A Wadke, Abu T M Serajuddin, Harold Jacobson, LIEBERMAN H.A.; LACHMAN L.; SCHAWARTZ J.B., Pharmaceutical Dosage Forms: Tablets, US, Marcel Dekker, (19890101), vol. 1, pages 1 - 73, ISBN 978-0-8247-8044-9, XP009184711-
OPPOSITION- DRESSMAN et al., "The BCS: Where Do We Go from Here?", Pharmaceutical Technology, (20010000), pages 68 - 76, XP055308304-
OPPOSITION- Edward Rudnic et al, "chapter 89 oral solid dosage forms", REMINGTON'S PHARMACEUTICAL SCIENCES, (19900000), pages 1633 - 1658, XP003032399-
OPPOSITION- "EMA Assessment Report for Eliquis®", Procedure No. EMA/H/C/002148, pages 1 - 62-
OPPOSITION- E. M. RUDNIC et al., "Tablet Dosage Forms in Modern", Tablet Dosage Forms in Modern Modern Pharmaceutics, (19960000), pages 333 - 359, XP009184716-
OPPOSITION- European Pharmacopoeia, (20080000), vol. 6.5, pages 4759 - 4765-
OPPOSITION- Frost, C., Et Al, "[P-M-665] Apixaban is an oral direct, factor Xa inhibitors: single dose safety, pharnacokinetics and pharmacodynamics in healthy subjects", J. Thromb. Haemost, (20070709), XP055640220-
OPPOSITION- Gibaldi, "Biopharmaceutics and Clinical Pharmacokinetics", (19910101), page 51, (20161007), XP055308521-
OPPOSITION- G. L. AMIDON et al., "A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability", Pharmaceutical Research, (19950000), vol. 12, no. 3, pages 413 - 420, XP055640443-
OPPOSITION- "Guideline on the investigation of bioequivalence", Committee of Medical Products for Human Use, Guidelines on the Investigation of Bioequivalence, (20100100), pages 1 - 27-
OPPOSITION- Herbert A . Lieberman Et Al., "Pharmaceutical Dosage Forms - Tablets", (19890101), pages 1 - 24, (20160307), XP055255581-
OPPOSITION- James Swarbrick Et Al., "Tablet Formulation", Encyclopedia of Pharmaceutical Technology, 2nd edition, (20020101), pages 2701 - 2712, ISBN 978-0-8247-2824-3, XP055308380-
OPPOSITION- J. DRESSMANN et al., "The BCS: Where Do We Go from Here", Pharmaceutical Technology, (20010700), XP055308304-
OPPOSITION- Jennifer Dressman, "The BCS: Where Do We Go from Here?", Pharm Tech, (20010701), pages 68 - 76, XP055308304-
OPPOSITION- Joseph P. Remington, "Dissolution", Joseph P. Remington, Gennaro Alfonso R., Remington: the science and practice of pharmacy, Easton, Pennsylvania, Mack Publishing Company, (19950101), page 2pp, 595, ISBN 978-0-912734-04-0, XP055282825-
OPPOSITION- J. SWARBRICK et al., Encyclopedia of Pharmaceutical Technology, (20020000), vol. 3, pages 2701 - 2712, XP055308380-
OPPOSITION- K. H. BAUER et al., "Pharmazeutische Technologie", Pharmazeutische Technologie, (19970000), pages 209 - 210 , 365, XP055308591-
OPPOSITION- Kurt H. Bauer Et Al., "Chapter 6 and 7", Pharmazeutische Technologie, (19970101), pages 178, 208 - 211, ISBN 978-3-7741-0638-3, XP055308166-
OPPOSITION- Kurt H, Bauer, Et Al, "Löslichkeit", Pharmazeutische Technologie, 5. Auflage, (19970101), pages 209 - 210, 365, ISBN 978-3-437-25630-1, XP055641330-
OPPOSITION- LASSEN MR et al., "The efficacy and safety of apixaban, an oral, direct factor Xainhibitor, as thromboprophylaxis in patients following total knee replacement", J Thromb Haemost, (20070915), vol. 5, pages 2368 - 75, XP055766071-
OPPOSITION- "Light Diffraction Measurement of Particle Size", US Pharmacopeia, (20150501), pages 294 - 299, XP055241392-
OPPOSITION- L. LACHMANN et al., The Theory and Practice of Industrial Pharmacy, Philadelphia, (19860000), pages 221 - 222, XP055308588-
OPPOSITION- L. Lachmann Et Al., "The Theory and Practice of Industrial Pharmacy", The Theory and Practice of Industrial Pharmacy, (19860101), pages 221 - 222, XP055308588-
OPPOSITION- M. E. Aulton, M. Ashford, "Bioavailability - physicochemical and dosage form factors", Aulton's Pharmaceutics, The Design and Manufacture of Medicines, 3rd edition, (20070101), pages 286 - 449, ISBN 978-0-443-10107-6, XP055308287-
OPPOSITION- M.E. Aulton, "pharmaceutical preformulation: the physicochemical properties of drug substances", Pharmaceutics, The Science of Dosage Form Design, (20020101), Pharmaceutics, The Science of Dosage Form Design, (20160809), XP055294349-
OPPOSITION- Michael E Aulton, "The design of Dosage Forms", Pharmaceutics: The Science of Dosage Form Design, Churchill, (19880101), pages 1 - 56, XP055765151-
OPPOSITION- "micronize", page 1, merriam-webster, URL: https://www.merriam-webster.com/dictionary/micronize-
OPPOSITION- M.R. Lassen, B. L. Davidson, A. Gallus, G. Pineo, J. Ansell, D . Deitchman, "The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement1", Journal of Thrombosis and Haemostasis, (20070101), vol. 5, pages 2368 - 2375, XP055754069-
OPPOSITION- Nor Hafizah Hj Annuar et al, "Effects of Sample Conditions on Multi-Particle Size Analysis using Laser Diffraction Technique", SCIENTIA BRUNEIANA, (20100000), pages 19 - 26, XP003035190-
OPPOSITION- "Oral Solid Dosage Forms", Remington's Pharmaceutical Sciences, (19900000), pages 1633 - 1658, XP002969032-
OPPOSITION- "Particle size analysis-laser diffraction methods", International Standard ISO 13320-1, (19991101), XP055766894-
OPPOSITION- Raymond C Rowe, Et Al., "Sodium lauryl sulfate", Handbook of Pharmaceutical Excipients, (20060101), pages 687 - 689, XP055466147-
OPPOSITION- Remington's Pharmaceutical Science, (19900000), pages 1633 - 1658, XP003032399-
OPPOSITION- RITSCHEL et al., Die Tablette, (20020000), pages 122 ; 226 - 229 ; 260-266, XP055754371-
OPPOSITION- Rudnic E M, Kottke M K, "CHAPTER 10: Tablet Dosage Forms", Rudnic E M, Kottke M K, Gilbert S Banker, Christopher T Rhodes (eds.), Modern Pharmaceutics (third edition), Marcel Dekker, (19960101), pages 333 - 394, ISBN 0-8247-9371-4, XP009184716-
OPPOSITION- "Section 2.9.31 - Particle Size Analysis by Laser Light Diffraction", European Pharmacopoeia 6.0,, (20070723), pages 311 - 314, XP055638472-
OPPOSITION- Serno Peter, Kleinebudde, P. And Knop, K., "Granulieren - Grundlagen, Verfahren, Formulierungen", (20070101), page 144, XP055777548-
OPPOSITION- Stojanovic Et Al, "determination of particle size distributions by laser diffraction", Technics - New Materials, (20120101), pages 11 - 20, Technics - New Materials, URL: http://www.itn.sanu.ac.rs/opus4/frontdoor/deliver/index/docId/413/file/Stojanovic_Technics_67_11-20.pdf, (20161003), XP055307143-
OPPOSITION- Sucker, Et Al, "3.4.2 Feste Arzneiformen", Pharmazeutische Technologie, Georg Thieme verlag, (19910101), pages 158 - 161, XP055640651-
OPPOSITION- SUCKER et al., Pharmazeutische Technologie, Stuttgart, (19910000), pages 158 - 161, XP055308164-
OPPOSITION- SWARBRICK et al., Encyclopedia of Pharmaceutical Technology, (20020000), vol. 3, pages 2701 - 2012, XP055308380-
OPPOSITION- The New England Journal of Medicine, N Engl J Med, (20110000), vol. 365, pages 981 - 92-
OPPOSITION- U. V. BANAKAR, "Factors That Influence Dissolution Testing", PHARMACEUTICAL DISSOLUTION TESTING, (19920000), pages 136 - 137 and 144-145, XP055308585-
OPPOSITION- U. V. Banakar, "Polymorphism", Pharmaceutical Dissolution Testing, Marcel Dekker, (19920101), pages 136, 137, 144 - 145, XP055641322-
OPPOSITION- "Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System", Guidance for Industry, (20000800), XP055640590-
OPPOSITION- W.A. Ritschel, A.Bauer-Brandl, "Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung /Passage/", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, Editio Cantor Verlag, (20020101), pages 2pp, 122, 226 - 266, XP055754371-
OPPOSITION- W. A. RITSCHEL et al., "Chapter 3 & 4", Die Tablette Handbuch der Entwicklung, Herstellung und Qualitätssicherung, (20020000), pages 235 - 241 , 256-259, XP055308574-
OPPOSITION- Y. TSUME et al., "the biowaiver extension for BCS Class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate release drugs predicted by computer simulation", Molecular Pharmaceutics, vol. 7, no. 4, pages 1235 - 1243, XP055308518-
OPPOSITION- "Zerkleinern", Römpp Lexikon Chemie, (19990000), vol. 6, page 5056-
OPPOSITION- Zheng, "overview of dry granulation processes and equipment design", Formulation and analytical development for low-dose oral drug products, Wiley, (20090101), pages 119 - 122, XP055765171-
OPPOSITION- Z. STOJANOVIC et al., "determination of particle size distributions by laser diffraction", Technics-New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVIC et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics - New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVIC et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics-New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- Z. STOJANOVI? et al., "Determination of Particle Size Distributions by Laser Diffraction", Technics - New Materials, (20120000), vol. 21, pages 11 - 20, XP055307143-
OPPOSITION- James E. Polli et al, "Summary workshop report: Biopharmaceutics classification system—implementation challenges and extension opportunities", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US, (20040601), vol. 93, no. 6, doi:10.1002/jps.20064, ISSN 0022-3549, pages 1375 - 1381, XP055308381
OPPOSITION- DRESSMAN et al., Journal of Pharmaceutical Sciences, (19850000), vol. 74, pages 588 - 589, XP055308397
OPPOSITION- J.B. Dressman, G.L. Amidon, D. Fleisher, "Absorption Potential: Estimating the Fraction Absorbed for Orally Administered Compounds", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US, (19850501), vol. 74, no. 5, doi:10.1002/jps.2600740523, ISSN 0022-3549, pages 588 - 589, XP055308397
OPPOSITION- S. Stegemann, F. Leveiller, D. Franchi, H. De Jong, H. Lindén, "When poor solubility becomes an issue: From early stage to proof of concept", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL, (20070801), vol. 31, no. 5, doi:10.1016/j.ejps.2007.05.110, ISSN 0928-0987, pages 249 - 261, XP055765093
OPPOSITION- STEGEMANN et al., Eur J Pharm Sci, (20070000), pages 249 - 261, XP055765093
OPPOSITION- STEGEMANN et al., "When poor solubility becomes an issue: From early stage to proof of concept", Eur J Pharm Sc i, (20070719), vol. 31, pages 249 - 261, XP022163590
OPPOSITION- Papadopoulou, V. ; Valsami, G. ; Dokoumetzidis, A. ; Macheras, P., "Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): Theoretical basis and practical examples", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, NL, (20080901), vol. 361, no. 1-2, doi:10.1016/j.ijpharm.2008.05.021, ISSN 0378-5173, pages 70 - 77, XP023316061
OPPOSITION- Henning H Blume, Barbara S Schug, "The biopharmaceutics classification system (BCS): Class III drugs — better candidates for BA/BE waiver?", European Journal of Pharmaceutical Sciences, Elsevier Amsterdam, NL, NL, (19991201), vol. 9, no. 2, doi:10.1016/S0928-0987(99)00076-7, ISSN 0928-0987, pages 117 - 121, XP055308358
OPPOSITION- H. H. BLUME et al., "The biopharmaceutics classification system (BCS): Class III drugs better candidates for BA / BE waiver", European Journal of Pharmaceutical Sciences, (19990000), vol. 9, doi:10.1016/S0928-0987(99)00076-7, pages 117 - 121, XP055308358
OPPOSITION- D. J. PINTO, "Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1- yl)phenyl)-4,5,6,7-tetrahydro-1 H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", J. Med. Chem., (20070000), vol. 50, doi:10.1021/jm070245n, pages 5339 - 5356, XP007915445
OPPOSITION- Pinto D, et al, "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", Journal of Medicinal Chemistry, American Chemical Society, (20070101), vol. 50, doi:10.1021/jm070245n, ISSN 0022-2623, pages 5339 - 5356, XP007915445
OPPOSITION- PINTO et al., "Discovery of 1-[4-(Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa", J. Med. Chem., (20070000), vol. 50, pages 5339 - 5356, XP007915445
OPPOSITION- PINTO et al., "Discovery of 1-(4-Methoxyphenyl)....", J. Med Chem, (20070000), vol. 50, doi:10.1021/jm070245n, pages 5339 - 5356, XP007915445
OPPOSITION- Lawrence X Yu, Amidon Gordon L, Polli James E, Zhao Hong, Conner Dale P, Shah Vinod P, Lesko Lawrence J, Chen Mei-Ling, Lee Vincent H L, Hussain Ajaz S, "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", Pharmaceutical Research, (20020701), vol. 19, no. 7, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- Lawrence X Yu et al, "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions", Pharmaceutical Research, (20020701), vol. 19, no. 7, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- L. X. YU et al., "Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions1", Pharmaceutical Research, (20020700), vol. 19, no. 7, doi:10.1023/a:1016473601633, pages 921 - 925, XP055308362
OPPOSITION- M. R. LASSEN et al., "Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement", The New England Journal of Medicine, (20090000), vol. 361, pages 594 - 604, XP055308399
OPPOSITION- P. BOWEN, "Particle Size Distribution Measurement from Millimeters to Nanometers and from Rods to Platelets", Journal of Dispersion Science and Technology, (20020000), vol. 23, no. 5, doi:10.1081/DIS-120015368, pages 647 - 652, XP009102859
OPPOSITION- Georgia Charkoftaki, Et Al, "Biopharmaceutical Classification Based on Solubility and Dissolution: A Reappraisal of Criteria for Hypothesis Models in the Light of the Experimental Observations", BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, NORDIC PHARMACOLOGICAL SOCIETY, COPENHAGEN, DK, COPENHAGEN, DK, (20100301), vol. 106, no. 3, doi:10.1111/j.1742-7843.2009.00506.x, ISSN 1742-7835, pages 168 - 172, XP055765163
OPPOSITION- TURPIE ALEXANDER ET AL, "Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases", Arterioscler Thromb Vasc Biol., (20070000), vol. 27, pages 1238 - 1247, XP002672841
OPPOSITION- APPRAISE STEERING COMMITTEE AND INVESTIGATORS, "Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination with Antiplatelet After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial", Circulation, (20090000), vol. 119, no. 22, doi:10.1161/CIRCULATIONAHA.108.832139, pages 2877 - 85, XP055636386
OPPOSITION- Yu Lawrence X.; Ellison Christopher D.; Conner Dale P.; Lesko Larry J.; Hussain Ajaz S., "Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs", AAPS PharmSci, Springer New York, New York, New York, (20010901), vol. 3, no. 3, doi:10.1208/ps030324, pages 86 - 92, XP035718572
OPPOSITION- Cook Jack; Addicks William; Wu Yunhui Henry, "Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View", The AAPS Journal, Springer US, Boston, Boston, (20080524), vol. 10, no. 2, doi:10.1208/s12248-008-9036-5, pages 306 - 310, XP035718954
OPPOSITION- Kylie Lepic, Mark Crowther, "New Anticoagulants for the Prevention of Thromboembolism", Current Pharmaceutical Design, NL, (20101001), vol. 16, no. 31, doi:10.2174/138161210793563437, ISSN 1381-6128, pages 3472 - 3474, XP055308375
OPPOSITION- F. STORTI, "Particle size distributions by laser diffraction: sensitivi- ty of granular matter strength to analytical operating procedures", Solid Earth, (20100419), vol. 1, doi:10.5194/se-1-25-2010, pages 25 - 48, XP003027683

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents